Erasca (ERAS) Profit After Tax (2020 - 2026)
Erasca (ERAS) posted Profit After Tax of -$184.8 million for Q1 2026, down 534.65% on a QoQ basis from -$29.1 million in Q4 2025, and down 496.68% year-over-year from $46.6 million in Q1 2025.
Erasca (ERAS) Profit After Tax (2020 - 2026) Analysis & Trends
Erasca's Profit After Tax history runs 7 years deep, the most recent figure standing at -$184.8 million for Q1 2026.
- Quarterly Profit After Tax fell 496.68% year-over-year to -$184.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$278.4 million (down 77.31% YoY) and the FY2025 annual result came in at -$124.3 million, up 22.93% from the prior year.
- Profit After Tax was -$184.8 million for Q1 2026 at Erasca, down from -$29.1 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$29.1 million in Q4 2025 and bottomed at -$184.8 million in Q1 2026.
- A 5-year average of -$49.3 million and a median of -$33.7 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax soared 77.49% — and 2026, when it plunged 496.68%.
- Erasca's Profit After Tax stood at -$134.0 million in 2022, then surged by 77.49% to -$30.2 million in 2023, then dropped by 11.55% to -$33.7 million in 2024, then increased by 13.49% to -$29.1 million in 2025, then tumbled by 534.65% to -$184.8 million in 2026.
- Business Quant data shows ERAS's Profit After Tax at -$184.8 million in Q1 2026, -$29.1 million in Q4 2025, and -$30.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Erasca | 5.84 Bn | 5.84 Bn | - | -184.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -184.77 Mn |
| Dec 31, 2025 | -29.11 Mn |
| Sep 30, 2025 | -30.61 Mn |
| Jun 30, 2025 | -33.88 Mn |
| Mar 31, 2025 | -30.97 Mn |
| Dec 31, 2024 | -33.65 Mn |
| Sep 30, 2024 | -29.18 Mn |
| Jun 30, 2024 | -63.20 Mn |
| Mar 31, 2024 | -35.02 Mn |
| Dec 31, 2023 | -30.17 Mn |
| Sep 30, 2023 | -30.36 Mn |
| Jun 30, 2023 | -31.78 Mn |
| Mar 31, 2023 | -33.20 Mn |
| Dec 31, 2022 | -134.03 Mn |
| Sep 30, 2022 | -35.49 Mn |
| Jun 30, 2022 | -35.61 Mn |
| Mar 31, 2022 | -36.46 Mn |
| Dec 31, 2021 | -30.46 Mn |
| Sep 30, 2021 | -46.07 Mn |
| Jun 30, 2021 | -28.21 Mn |